43P Time to next treatment (TTNT) of first-line maintenance (1Lm) niraparib monotherapy in epithelial ovarian cancer (EOC) patients (pts) in the CHAR1ZMA study
| Autor: | Coleman, R.L., Salani, R., Boyle, T., Perhanidis, J., Lim, J., Kalilani, L., Schilder, J.M., Hurteau, J., Golembesky, A., Backes, F. |
|---|---|
| Zdroj: | In ESMO Open February 2023 8(1) Supplement 1 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|